NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
23. Mai 2023 01:00 ET
|
NMD Pharma
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
29. Juni 2022 08:00 ET
|
Codiak BioSciences, Inc.
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak...